INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer's DiseaseGlobeNewsWire • 11/14/22
INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business UpdateGlobeNewsWire • 11/02/22
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2GlobeNewsWire • 10/26/22
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmuneGlobeNewsWire • 10/19/22
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare ConferenceGlobeNewsWire • 09/07/22
INmune Bio, Inc's (INMB) CEO RJ Tesi on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business UpdateGlobeNewsWire • 08/03/22
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3GlobeNewsWire • 07/27/22
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's DiseaseGlobeNewsWire • 07/25/22
INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast CancerGlobeNewsWire • 06/16/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of INmune Bio, Inc. - INMBNewsfile Corp • 06/15/22
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 06/07/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of INmune Bio, Inc. - INMBNewsfile Corp • 05/28/22
INmune Bio stock plunges after clinical hold of IND of Alzheimer's treatment prompts analyst downgradeMarket Watch • 05/24/22
INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer's DiseaseGlobeNewsWire • 05/23/22
INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24thGlobeNewsWire • 05/18/22
INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on NeuroinflammationGlobeNewsWire • 05/10/22
INmune Bio's (INMB) CEO RJ Tesi on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/08/22
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business UpdateGlobeNewsWire • 05/05/22
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5GlobeNewsWire • 04/28/22